References
- Rang HP, Dale MM, Ritter JM. Neuroleptic drugs. I: Pharmaco-logy, 3rd edition. Edinburgh: Churchill Livingstone; 1995. p. 567–75.
- Delay J, Deniker P. Trente-Huit cas de psycoses traitées par la cure prolongée et continue de 4560 RP. Le Congrés des Al. et Neurol. de Langue Fr. I: Compte rendu du Congrés. Masson et Cie, Paris; 1952.
- Jorgensen HA. Medikamentell behandling av schizofreni. Tidsskr Nor Lxgeforen 2002;122:2206–9.
- Jorgensen HA. Antipsykotika. I: Vennerod AM, red. Norsk legemiddelhandbok for helsepersonell 2001. Oslo: Foreningen for utgivelse av norsk legemiddelhandbok; 2001. p. 806–15.
- Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. The Mount Sinai conference on the pharma-cotherapy of schizophrenia. Schiz Bull 2002;28:5–16.
- Weiden PJ, Iqbal N, Mendelowitz AJ, Tandon R, Zimbroff DL, Ross R. Best clinical practice with ziprasidone: Update after one year of experience. J Psychiat Pract 2002;8:8198.
- Merril Lynch research estimates and IMS. Pharmaceuticals. 2001 June.
- Weiden PJ, Casey DE. The road back: Working with those with severe mental illness, "Polypharmacy": Combining antipsychotic medications in the treatment of schizophrenia. J Prac Psych Behav Health 1999;5:229–33.
- Miller AL, Craig CS. Combination antipsychotics: Pros, cons, and questions. Schiz Bull 2002;28:105–9.
- Watson S, Young AH. The place of lithium salts in psychiatric practice 50 years on. Curr Opin Psychiatry 2001;14:57–63.
- Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harvard Rev Psychiatry 2002;10:59–75.
- McIntyre RS, Mancini DA, Parikh S, Kennedy SH. Lithium revisited. Can J Psychiatry 2001;46:322–7.
- Crow TJ. From Kraepelin to Kretschmer leavened by Schneider. The transition from categories of psychosis to dimensions of variation intrinsic in homo sapiens. Arch Gen Psychiatry 1998;55:502–4.